Compare · GLP-1 agonist
Amycretin vs Retatrutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Amycretin | Retatrutide | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere. | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. |
| Full profile → | Full profile → |
Amycretin
Amycretin is an investigational drug from Novo Nordisk that has generated some striking early-phase weight-loss numbers, which is exactly why it shows up on peptide forums and gray-market menus. It is a single-molecule ("unimolecular") peptide that activates two receptors at once — the GLP-1…
Retatrutide
Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.